This article is for research and educational purposes only. Not medical advice.
Cagrilintide is a once-weekly subcutaneous long-acting amylin analog developed by Novo Nordisk. It mimics the action of amylin, a gut peptide co-secreted with insulin by pancreatic beta cells in response to meals.
Cagrisema is a fixed-dose combination of cagrilintide and semaglutide (the GLP-1 agonist in Ozempic and Wegovy), delivered as a single weekly injection. The intent is to leverage two complementary satiety mechanisms (GLP-1 and amylin co-agonism) to drive greater weight loss than either drug alone.
This dual-mechanism approach is conceptually similar to tirzepatide's combination of GIP and GLP-1 receptor activation in a single peptide. The difference is that cagrisema combines two separate molecules, while tirzepatide is one molecule that hits two receptors. For broader context on dual- and triple-receptor approaches, our retatrutide vs semaglutide vs tirzepatide comparison covers the full mechanism-by-mechanism landscape.
Amylin is co-secreted with insulin from the pancreas after meals. It contributes to satiety through three mechanisms:
Endogenous amylin has a half-life of approximately 13 minutes. Pramlintide (Symlin), an existing amylin analog approved for type 1 and type 2 diabetes, requires multiple daily injections. Cagrilintide is engineered for once-weekly administration through pharmacokinetic modifications similar to those used to extend the half-life of semaglutide.
Combining amylin and GLP-1 agonism targets satiety through partially independent pathways. In theory, this should produce more weight loss than either alone, without the additive side-effect burden that comes from simply increasing the dose of a single class.
For the foundational GLP-1 mechanism, see our piece on how GLP-1 agonists work.
REDEFINE-1 randomised adults with obesity (BMI ≥30 kg/m², or ≥27 with comorbidities) without type 2 diabetes to cagrisema or comparator arms over 68 weeks. Headline results:
The cagrisema 22.7% result is clinically significant, meaningfully above semaglutide monotherapy at 16.1%, and competitive with tirzepatide's SURMOUNT-1 result of ~20.9%.
It was also widely characterised as disappointing. Novo Nordisk's prior communications had set market expectations toward a 25% weight loss figure, and the company's share price reacted negatively to the readout. The gap between "clinically excellent" and "below market expectations" is the headline story.
A subset analysis showed that participants who reached the maximum dose with optimal adherence achieved closer to 25% weight loss, while the intent-to-treat average was pulled down by participants who titrated more slowly or discontinued. This is a recurring pattern in obesity trials, the gap between trial-protocol weight loss and intent-to-treat weight loss is meaningful.
REDEFINE-2 evaluated cagrisema in adults with type 2 diabetes inadequately controlled on metformin. Over 68 weeks:
Weight loss in the T2D population is typically lower than in non-diabetic obesity populations across all GLP-1 trials, a well-established pattern. The 13.7% cagrisema result in T2D is approximately double what semaglutide 2.4 mg achieves in the same population in cross-trial comparison.
The side-effect profile follows the GLP-1 class signature, with a slight amylin-related tilt:
Cagrilintide's amylin mechanism adds a modest additional gastric-emptying delay, which may amplify nausea in the titration phase. Our GLP-1 side effects management guide covers the practical strategies that apply across this entire drug class.
Three factors made REDEFINE-1's outcome read as a setback rather than a triumph:
1. Market expectations were anchored to ~25%. Novo's pre-readout communications referenced potential weight loss "above 25%" based on Phase 2 data. The 22.7% intent-to-treat result undershot that anchor by ~2.5 percentage points.
2. The competitive frame is tirzepatide and retatrutide. Tirzepatide already delivers ~20.9%. Retatrutide's Phase 2 data showed ~24.2% at 48 weeks. The window for cagrisema to be "best in class" was narrow before REDEFINE-1; the actual result puts it firmly in the middle of the next-generation pack rather than at the front.
3. Combination drug pricing and complexity. A fixed-dose combination of two molecules has higher cost-of-goods and more complex regulatory positioning than a single-molecule competitor. The bar for combination drugs to be commercially successful is therefore higher.
None of this means cagrisema is clinically unimpressive. It means the gap between trial outcome and pre-set commercial expectation matters as much as the trial outcome itself.
Novo Nordisk is expected to file marketing authorisation applications for cagrisema with regulatory bodies in late 2025 and 2026. The Australian path involves:
Cagrilintide as a monotherapy may follow a separate path, though Novo's commercial priorities will likely focus on cagrisema. For the broader Australian GLP-1 access landscape, see our Ozempic Australia 2026 overview and our Wegovy PBS listing Australia 2026 piece.
For patients already responding well to semaglutide or tirzepatide, cagrisema does not represent an immediately compelling reason to switch. The differences in efficacy are modest, and class-comparable side effects mean any switch carries re-titration burden.
For patients with inadequate response to semaglutide monotherapy at the maximum 2.4 mg dose, cagrisema may offer additional weight loss, but only when available, which in Australia means not before 2027 at earliest.
For patients planning to discontinue GLP-1 therapy, the post-GLP-1 maintenance protocol discussion is unchanged by the arrival of cagrisema. Weight regain after discontinuation remains a class-wide reality regardless of which GLP-1 was used.
Cagrilintide and cagrisema represent a clinically meaningful evolution of injectable obesity pharmacotherapy. The amylin co-agonism mechanism is biologically sound and the trial outcomes are competitive with existing best-in-class drugs.
The market characterisation of "disappointing" reflects pre-readout expectations rather than the absolute clinical picture. Cagrisema delivers approximately 22.7% mean weight loss in obesity at 68 weeks, meaningfully more than semaglutide alone, modestly less than the upper bound expected of retatrutide, and within striking range of tirzepatide.
For Australian researchers and clinicians, the practical questions are regulatory timing (2026 to 2027 at the earliest), commercial positioning (combination drug economics versus single-molecule competitors), and whether the modest efficacy edge over semaglutide justifies the additional cost and complexity for any given patient.
Eli Lilly's orforglipron is the first non-peptide oral GLP-1 agonist with full Phase 3 data. What ATTAIN-1 and ACHIEVE-1 show on weight loss and Australia.
An evidence-based guide to natural weight loss in Australia: caloric balance, diet, exercise, sleep, hormones, GLP-1 medications, and peptide science.
The SELECT trial showed semaglutide cut MACE by 20% in non-diabetic patients with obesity and CV disease. Mechanisms, findings, and Australian PBS access.